This clearance allows Encoded to begin clinical trials of the gene therapy candidate designed to treat Sodium channel protein type 1 subunit alpha (SCN1A)+ Dravet syndrome. In addition ...

in the SCN1A gene. Data from the studies have shown that treatment with zorevunersen led to substantial and sustained reductions in seizure frequency and continuous improvements in multiple ...

Millie-Mae has a mutation in the SCN1A gene and routine genetic testing would have eventually revealed this. But Prof Raymond said this would have taken many more months, and with other conditions ...

In around 80% of cases, Dravet syndrome is caused by defects in a gene coding for a sodium channel – SCN1A – which is required for the proper functioning of neurons in the brain. CAMP4's drug ...